

Table S1: Seroprevalence of neglected tropical diseases (NTDs), enteric protozoa, helminths, mosquito-borne diseases, and vaccine preventable diseases (VPDs), stratified by sex and age, Niue 2025

Disease (antigen)			Sex				Age (years)						P-value 1	P-value 2
	Total		Males		Females		<20		20-49		≥50			
	(n=750)		(n=353)		(n=397)		(n=244)		(n=240)		(n=266)			
	N	% (95% CI)	N	% (95% CI)	N	% (95% CI)	N	% (95% CI)	N	% (95% CI)	N	% (95% CI)		
Seropositive for NTDs														
Lymphatic filariasis (<i>Bm14</i>)	5	0.7 0.3-1.6	4	1.1 0.4-3	1	0.3 0-1.8	1	0.4 0.1-2.9	2	0.8 0.2-3.3	2	0.8 0.2-3	0.14	0.83
Lymphatic filariasis (<i>Wb123</i>)	6	0.8 0.4-1.8	3	0.8 0.3-2.6	3	0.8 0.2-2.3	2	0.8 0.2-3.2	1	0.4 0.1-2.9	3	1.1 0.4-3.5	0.89	0.67
Yaws (<i>TmpA</i> and <i>Rp17</i>) [∞]	0	0 -	0	0 -	0	0 -	0	0 -					-	-
Trachoma (<i>Pgp3</i>) [∞]	5	0.7 0.3-1.6	2	0.6 0.1-2.2	3	0.8 0.2-2.3	2	0.8 0.2-3.2					0.75	-
Cysticercosis (<i>T24H</i>)	20	2.7 1.7-4.1	7	2 0.9-4.1	13	3.3 1.9-5.6	7	2.9 1.4-5.9	6	2.5 1.1-5.5	7	2.6 1.3-5.4	0.27	0.97
Taeniasis (<i>Es33</i>)	5	0.7 0.3-1.6	3	0.8 0.3-2.6	2	0.5 0.1-2	1	0.4 0.1-2.9	2	0.8 0.2-3.3	2	0.8 0.2-3	0.56	0.83
Strongyloidiasis (<i>SsIR</i>)	14	1.9 1.1-3.1	8	2.3 1.1-4.5	6	1.5 0.7-3.3	0	0 -	5	2.1 0.9-4.9	9	3.4 1.8-6.4	0.45	0.02
Seropositive for arboviruses														
Dengue (serotype DENV-1) <i>DengNS1 sero1</i>	200	26.7 23.6-30.0	98	27.8 23.3-32.7	102	25.7 21.6-30.2	9	3.7 1.9-7	78	32.5 26.8-38.7	113	42.5 36.6-48.5	0.52	<0.001
Dengue (serotype DENV-2) <i>DengNS2 sero2</i>	158	21.1 18.3-24.1	74	21 17-25.5	84	21.2 17.4-25.5	5	2 0.9-4.8	44	18.3 13.9-23.8	109	41 35.2-47	0.95	<0.001
Dengue (serotype DENV-3) <i>DengNS3 sero3</i>	162	21.6 18.8-24.7	77	21.8 17.8-26.4	85	21.4 17.6-25.7	6	2.5 1.1-5.4	45	18.8 14.3-24.2	111	41.7 35.9-47.8	0.89	<0.001
Dengue (serotype DENV-4) <i>DengNS4 sero4</i>	263	35.1 31.7-38.6	122	34.6 29.8-39.7	141	35.5 30.9-40.4	12	4.9 2.8-8.5	88	36.7 30.8-43	163	61.3 55.3-67	0.78	<0.001
Chikungunya (<i>Chik E1</i>)	24	3.2 2.2-4.7	13	3.7 2.1-6.2	11	2.8 1.5-4.9	7	2.9 1.4-5.9	14	5.8 3.5-9.6	3	1.1 0.4-3.5	0.48	0.01
Zika (<i>Zika NS1</i>)	23	3.1 2.0-4.6	10	2.8 1.5-5.2	13	3.3 1.9-5.6	4	1.6 0.6-4.3	16	6.7 4.1-10.6	3	1.1 0.4-3.5	0.73	<0.001
Seropositive for VPDs														
SARS CoV2 (<i>RBD591</i>) [‡]	734	97.9 96.5-98.7	342	96.9 94.5-98.3	392	98.7 97-99.5	231	94.7 91-96.9	239	99.6 97.1-99.9	264	99.2 97-99.8	0.08	<0.001

SARS CoV2	746	99.5	351	99.4	395	99.5	243	99.6	239	99.6	264	99.2	0.91	0.83
(<i>Spike</i>) [‡]		98.6-99.8		97.8-99.9		98-99.9		97.1-99.9		97.1-99.9		97-99.8		
SARS CoV2	465	62	217	61.5	248	62.5	175	71.7	147	61.3	143	53.8	0.78	<0.001
(<i>N</i>) [‡]		58.5-65.4		56.3-66.4		57.6-67.1		65.7-77		54.9-67.2		47.7-59.7		
Measles virus 0.01 IU/mL [‡]	741	98.8	347	98.3	394	99.2	242	99.2	233	97.1	266	100	0.24	0.01
(<i>MeV</i>)		97.7-99.4		96.3-99.2		97.7-99.8		96.8-99.8		94-98.6		-		
Rubella virus 0.01 IU/mL [‡]	736	98.1	346	98	390	98.2	243	99.6	235	97.9	258	97	0.82	0.09
(<i>RuV</i>)		96.9-98.9		95.9-99.1		96.3-99.2		97.1-99.9		95.1-99.1		94.1-98.5		
Tetanus toxoid 0.01 IU/mL [‡]	716	95.5	343	97.2	373	94	239	98	228	95	249	93.6	0.03	0.06
(<i>Tet</i>)		93.7-96.7		94.8-98.5		91.1-95.9		95.2-99.1		91.4-97.1		89.9-96		
Tetanus toxoid 0.1 IU/mL [‡]	554	73.9	287	81.3	267	67.3	195	79.9	180	75	179	67.3	<0.001	0.01
(<i>Tet</i>)		70.6-76.9		76.9-85		62.5-71.7		74.4-84.5		69.1-80.1		61.4-72.7		
Diphtheria toxoid 0.01/mL [‡]	509	67.9	247	61.9	262	59.2	224	91.8	165	68.8	120	45.1	0.24	<0.001
(<i>Dip</i>)		64.4-71.1		55.3-68.2		52.9-65.3		87.6-94.7		62.6-74.3		39.2-51.1		
Diphtheria toxoid 0.1/mL [‡]	248	33.1	130	28.0	118	21.0	145	59.4	72	30	31	11.7	0.04	<0.001
(<i>Dip</i>)		29.8-36.5		22.4-34.3		16.3-26.7		53.1-65.4		24.5-36.1		8.3-16.1		
Pertussis 5mIU/mL [‡]	750	100	100	100	397	100	244	100	240	100	266	100	-	-
(<i>Pt</i>)		-		-		-		-		-		-		
Seropositive for enteric protozoa														
Cryptosporidium	515	68.7	231	65.4	284	71.5	104	42.6	184	76.7	227	85.3	0.07	<0.001
(<i>Cp17</i> or <i>Cp23</i>)		65.2-71.9		60.3-70.2		66.9-75.8		36.5-48.9		70.9-81.6		80.5-89.1		
Giardiasis	31	4.1	13	3.7	18	4.5	9	3.7	7	2.9	15	5.6	0.56	0.28
(<i>VSP3</i> or <i>VSP5</i>)		2.9-5.8		2.1-6.2		2.9-7.1		1.9-7		1.4-6		3.4-9.2		

Table S2: Seroprevalence of neglected tropical diseases (NTDs), enteric protozoa, helminths, mosquito-borne diseases, and vaccine preventable diseases (VPDs), stratified by recruitment site, Niue 2025

Disease (antigen)	Recruitment site						P-value 1
	Total		Alofi		Villages		
	(n=750)		(n=213)		(n=537)		
	N	% (95% CI)	N	% (95% CI)	N	% (95% CI)	
Seropositive for NTDs							
Lymphatic filariasis (<i>Bm14</i>)	5	0.7 0.3-1.6	2	0.9 0.2-3.7	3	0.6 0.2-1.7	0.56
Lymphatic filariasis (<i>Wb123</i>)	6	0.8 0.4-1.8	0	0	6	1.1 0.5-2.5	0.12
Yaws (<i>TmpA</i> and <i>Rp17</i>) [∞]	0	0 -	0	0 -	0	0 -	-
Trachoma (<i>Pgp3</i>) [∞]	5	0.7 0.3-1.6	1	0.5 0.1-3.3	1	0.2 0-1.3	0.5
Cysticercosis (<i>T24H</i>)	20	2.7 1.7-4.1	7	3.3 1.6-6.8	13	2.4 1.4-4.1	0.51
Taeniasis (<i>Es33</i>)	5	0.7 0.3-1.6	1	0.5 0.1-3.3	4	0.7 0.3-2	0.68
Strongyloidiasis (<i>SsIR</i>)	14	1.9 1.1-3.1	3	1.4 0.5-4.3	11	2 1.1-3.7	0.56
Seropositive for arboviruses							
Dengue (serotype DENV-1) <i>DengNS1 sero1</i>	200	26.7 23.6-30.0	65	30.5 24.7-37.1	135	25.1 21.6-29	0.13
Dengue (serotype DENV-2) <i>DengNS2 sero2</i>	158	21.1 18.3-24.1	58	27.2 21.6-33.6	100	18.6 15.5-22.1	0.01
Dengue (serotype DENV-3) <i>DengNS3 sero3</i>	162	21.6 18.8-24.7	58	27.2 21.6-33.6	104	19.4 16.2-22.9	0.02
Dengue (serotype DENV-4) <i>DengNS4 sero4</i>	263	35.1 31.7-38.6	84	39.4 33.1-46.2	179	33.3 29.5-37.4	0.11
Chikungunya (<i>Chik E1</i>)	24	3.2 2.2-4.7	11	5.2 2.9-9.1	13	2.4 1.4-4.1	0.054
Zika (<i>Zika NS1</i>)	23	3.1 2.0-4.6	15	7 4.3-11.4	8	1.5 0.7-3	<0.001
Seropositive for VPDs							
SARS CoV2 (<i>RBD591</i>) [‡]	734	97.9 96.5-98.7	208	97.7 94.5-99	526	98 96.3-98.9	0.8

SARS CoV2	746	99.5	213	100	533	99.3	0.21
(<i>Spike</i>) [‡]		98.6-99.8		-		98-99.7	
SARS CoV2	465	62	137	64.3	328	61.1	0.41
(<i>N</i>) [‡]		58.5-65.4		57.6-70.5		56.9-65.1	
Measles virus 0.01 IU/mL [‡]	741	98.8	209	98.1	532	99.1	0.28
(<i>MeV</i>)		97.7-99.4		95.1-99.3		97.8-99.6	
Rubella virus 0.01 IU/mL [‡]	736	98.1	208	97.7	528	98.3	0.54
(<i>RuV</i>)		96.9-98.9		94.5-99		96.8-99.1	
Tetanus toxoid 0.01 IU/mL [‡]	716	95.5	201	94.4	515	95.9	0.36
(<i>Tet</i>)		93.7-96.7		90.3-96.8		93.9-97.3	
Tetanus toxoid 0.1 IU/mL [‡]	554	73.9	159	74.6	395	73.6	0.76
(<i>Tet</i>)		70.6-76.9		68.3-80.1		69.7-77.1	
Diphtheria toxoid 0.01/mL [‡]	509	67.9	360	70	149	67	0.44
(<i>Dip</i>)		64.4-71.1		62.9-70.9		63.5-75.7	
Diphtheria toxoid 0.1/mL [‡]	248	33.1	168	31.3	80	37.6	0.1
(<i>Dip</i>)		29.8-36.5		27.5-35.3		31.3-44.3	
Pertussis 5mIU/mL [‡]	750	100	213	100	537	100	-
(<i>Pt</i>)		-		-		-	
Seropositive for enteric protozoa							
Cryptosporidium	515	68.7	132	62	383	71.3	0.01
(<i>Cp17</i> or <i>Cp23</i>)		65.2-71.9		55.2-68.3		67.3-75	
Giardiasis	31	4.1	9	4.2	22	4.1	0.94
(<i>VSP3</i> or <i>VSP5</i>)		2.9-5.8		2.2-7.9		2.7-6.1	

Table S3a: Logistic regression of demographic and behavioural factors associated with seropositivity to neglected tropical diseases, Niue 2025. Light grey cells were not significant in the final multivariable model. Age associations were not estimated for trachoma as analysis was restricted to those aged ≤14 years only.

	Lymphatic filariasis				Trachoma		Helminths					
	<i>Bm14</i>		<i>Wb123</i>		<i>Pgp3</i>		Strongyloidiasis		Cysticercosis		Taeniasis	
	Ab-positive		Ab-positive [#]		Ab-positive		Ab-positive [^]		Ab-positive		Ab-positive	
	aOR (95% CI)	P- value	aOR (95% CI)	P- value	aOR (95% CI)	P- value	aOR (95% CI)	P- value	aOR (95% CI)	P- value	aOR (95% CI)	P- value
Age (years)*		0.77		0.68						0.82		0.95
<20	REF		REF						REF		REF	
20-49	2.4 (0.2-26.4)	0.49	0.5 (0.0-5.7)	0.59					2.1 (0.2-23.5)	0.55	0.8 (0.3-2.5)	0.76
50+	2.1 (0.2-23.9)	0.54	1.4 (0.2-8.4)	0.72					1.9 (0.2-21.0)	0.61	0.9 (0.3-2.6)	0.83
Sex												
Male	REF		REF		REF		REF		REF		REF	
Female	0.2 (0.0-1.9)	0.17	0.9 (0.2-4.5)	0.89	0.9 (0.1-14.7)	0.95	0.7 (0.2-1.9)	0.44	0.6 (0.1-3.4)	0.53	1.7 (0.7-4.3)	0.26
Age x Sex interaction												
<20 years x female												
20-49 years x female												
50+ years x female												
Recruitmant site												
Villages	REF				REF		REF		REF		REF	
Alofi	1.7 (0.3-10.3)	0.57			2.5 (0.2-40.5)	0.51	0.7 (0.2-2.4)	0.55	0.6 (0.1-5.7)	0.69	1.4 (0.5-3.5)	0.49

*Global p-value for age group obtained using Wald χ^2 test (df=2).
[#] Recruitment site omitted because of collinearity. [^]Age group omitted because of collinearity.

Table S3b: Logistic regression of demographic and behavioural factors associated with seropositivity to arboviruses, Niue 2025. Light grey cells were not significant in the final multivariable model. Age associations were not estimated for trachoma as analysis was restricted to those aged ≤14 years only.

	Arboviruses											
	DENV-1 Ab-positive		DENV-2 Ab-positive		DENV-3 Ab-positive		DENV-4 Ab-positive		Zika Ab-positive		Chikungunya Ab-positive	
	aOR (95% CI)	P- value	aOR (95% CI)	P- value	aOR (95% CI)	P- value	aOR (95% CI)	P- value	aOR (95% CI)	P- value	aOR (95% CI)	P- value
Age (years)*		<0.001		<0.001		<0.001		<0.001		0.001		0.02
<20	REF		REF		REF		REF		REF		REF	
20-49	13.3 (6.5-27.4)	<0.001	11.4 (4.4-29.4)	<0.001	9.7 (4.0-23.3)	<0.001	11.7 (6.2-22.3)	<0.001	4.7 (1.5-14.6)	0.007	2.2 (0.9-5.7)	0.09
50+	20.5 (10.1-41.9)	<0.001	35.93 (14.3-90.5)	<0.001	30.9 (13.2-72.6)	<0.001	32.6 (17.2-61.6)	<0.001	0.7 (0.2-3.3)	0.69	0.4 (0.1-1.6)	0.20
Sex												
Male	REF		REF		REF		REF		REF		REF	
Female	0.8 (0.5-1.1)	0.14	0.9 (0.6-1.3)	0.53	0.8 (0.6-1.2)	0.4	0.9 (0.6-1.3)	0.5	1.1 (0.5-2.7)	0.75	0.7 (0.3-1.7)	0.48
Age x Sex interaction												
<20 years x female												
20-49 years x female												
50+ years x female												
Recruitment site												
Villages	REF		REF		REF		REF		REF		REF	
Alofi	1.5 (1.0-2.2)	0.04	2.0 (1.3-3.1)	0.001	1.9 (1.3-2.9)	0.002	1.6 (1.1-2.4)	0.01	5.4 (2.2-13.0)	<0.001	2.2 (1.0-5.0)	0.06

*Global p-value for age group obtained using Wald χ^2 test (df=2).

Table S3c: Logistic regression of demographic and behavioural factors associated with seropositivity to vaccine-preventable diseases (VPDs), Niue 2025. Light grey cells were not significant in the final multivariable model.

	SARS CoV-2					
	RDB51 Ab-positive		Spike Ab-positive [#]		N Ab-positive	
	aOR (95% CI)	P- value	aOR (95% CI)	P- value	aOR (95% CI)	P- value
Age (years)*		0.004		0.83		<0.001
<20	REF		REF		REF	
20-49	12.7 (1.6-98.3)	0.02	1.0 (0.1-15.7)	0.98	0.6 (0.4-0.9)	0.02
50+	7.1 (1.6-31.7)	0.01	0.5 (0.0-6.0)	0.61	0.5 (0.3-0.7)	<0.001
Sex						
Male	REF		REF		REF	
Female	2.2 (0.7-6.5)	0.16	1.2 (0.2-8.3)	0.89	1.1 (0.8-1.5)	0.56
Age x Sex interaction						
<20 years x female						
20-49 years x female						
50+ years x female						
Recruitment site						
Villages	REF				REF	
Alofi	1.0 (0.3-3.0)	1.00			1.1 (0.8-1.6)	0.50

*Global p-value for age group obtained using Wald χ^2 test (df=2).

[#] Recruitment site omitted because of collinearity.

Table S3d: Logistic regression of demographic and behavioural factors associated with seropositivity to vaccine-preventable diseases (VPDs), Niue 2025. Light grey cells were not significant in the final multivariable model.

	Vaccine-preventable diseases											
	Diphtheria min Ab-positive		Diphtheria max Ab-positive		Tetanus min Ab-positive		Tetanus max Ab-positive		Measles Ab-positive [#]		Rubella Ab-positive	
	aOR (95% CI)	P- value	aOR (95% CI)	P- value	aOR (95% CI)	P- value	aOR (95% CI)	P- value	aOR (95% CI)	P- value	aOR (95% CI)	P- value
Age (years)*		<0.001		<0.001		0.09		0.66				0.15
<20	REF		REF		REF		REF				REF	
20-49	0.2 (0.1-0.3)	<0.001	0.3 (0.2-0.4)	<0.001	0.4 (0.1-1.2)	0.11	1.2 (0.6-2.4)	0.54			0.2 (0.0-1.6)	0.13
50+	0.1 (0.0-0.1)	<0.001	0.1 (0.1-0.1)	<0.001	0.3 (0.1-0.9)	0.03	1.3 (0.7-2.5)	0.39			0.1 (0.0-1.0)	0.054
Sex												
Male	REF		REF		REF		REF		REF		REF	
Female	0.9 (0.7-1.3)	0.62	0.8 (0.6-1.1)	0.17	0.5 (0.2-1.0)	0.053	1.1 (0.6-2.2)	0.67	2.2 (0.6-9.0)	0.26	1.2 (0.4-3.5)	0.71
Age x Sex interaction*								0.002				
<20 years x female							REF					
20-49 years x female							0.4 (0.2-1.0)	0.06				
50+ years x female							0.2 (0.1-0.5)	<0.001				
Recruitment site												
Villages	REF		REF		REF		REF		REF		REF	
Alofi	1.1 (0.7-1.6)	0.73	1.3 (0.9-1.8)	0.22	0.7 (0.3-1.4)	0.30	1.0 (0.7-1.5)	0.82	0.5 (0.1-1.9)	0.31	0.7 (0.2-2.0)	0.48

*Global p-value for age group and interaction obtained using Wald χ^2 test (df=2).

[#] Age omitted because of collinearity.

multivariable model.

	Enteric protozoa			
	Cryptosporidium Ab-positive		Giardiasis Ab-positive	
	aOR (95% CI)	P- value	aOR (95% CI)	P- value
Age (years)		<0.001		0.29
<20	REF		REF	
20-49	4.4 (2.9-6.5)	<0.001	0.8 (0.3-2.1)	0.62
50+	7.7 (5.0-11.8)	<0.001	1.5 (0.7-3.6)	0.32
Sex				
Male	REF		REF	
Female	1.2 (0.9-1.7)	0.3	1.2 (0.6-2.6)	0.57
Age x Sex interaction				
<20 years x female				
20-49 years x female				
50+ years x female				
Recruitment site				
Villages	REF		REF	
Alofi	0.7 (0.5-1.0)	0.03	1.1 (0.5-2.3)	0.90

*Global p-value for age group and interaction obtained from logistic regression

Table S4a: Adjusted predicted probabilities of antigen positivity by recruitment site and age. Niue, 2025.

		<i>DENV-1</i>		<i>DENV-2</i>		<i>DENV-3</i>		Zika		Cryptosporidium	
Recruitment site	Age group (years)	Predicted probability (95% CI)	<i>P</i> -value	Predicted probability (95% CI)	<i>P</i> -value	Predicted probability (95% CI)	<i>P</i> -value	Predicted probability (95% CI)	<i>P</i> -value	Predicted probability (95% CI)	<i>P</i> -value
Villages	<20	3.2 (1.1-5.3)	0.003	1.6 (0.2-3)	0.03	1.9 (0.4-3.5)	0.02	0.7 (-0.1-1.5)	0.09	45.7 (38.8-52.5)	<0.001
	20-49	29.9 (23.8-36.1)	<0.001	15.2 (10.5-19.9)	<0.001	15.9 (11.1-20.6)	<0.001	3.3 (0.9-5.7)	0.007	78.8 (73.4-84.1)	<0.001
	50+	39.8 (33.4-46.1)	<0.001	36.4 (30-42.7)	<0.001	37.5 (31.1-43.9)	<0.001	0.5 (-0.1-1.2)	0.12	86.8 (82.7-90.9)	<0.001
Alofi	<20	4.8 (1.6-8.0)	0.004	3.1 (0.4-5.9)	0.03	3.6 (0.7-6.6)	0.02	3.7 (0-7.4)	0.048	35.9 (27.6-44.2)	<0.001
	20-49	39.3 (30.2-48.8)	<0.001	26.6 (18.3-34.9)	<0.001	26.4 (18.2-34.6)	<0.001	15.5 (7.3-23.7)	<0.001	71.2 (63.2-79.2)	<0.001
	50+	50.0 (40.7-59.2)	<0.001	53.6 (44-63.3)	<0.001	53.3 (43.7-62.9)	<0.001	2.8 (-0.4-6)	0.09	81.4 (75-87.7)	<0.001

Table S4b: Adjusted predicted probabilities of antigen positivity by age group. Niue, 2025

	SARS-CoV-2 (<i>RBD591</i>)		SARS-CoV-2 (<i>N</i>)		Tetanus min		Diphtheria min		Diphtheria max	
Age group (years)	Predicted probability (95% CI)	<i>P</i> -value	Predicted probability (95% CI)	<i>P</i> -value	Predicted probability (95% CI)	<i>P</i> -value	Predicted probability (95% CI)	<i>P</i> -value	Predicted probability (95% CI)	<i>P</i> -value
<20	94.7 (91.9-97.5)	<0.001	71.7 (66.1-77.4)	<0.001	98.0 (96.2-99.7)	<0.001	91.8 (88.4-95.2)	<0.001	59.4 (53.3-65.6)	<0.001
20-49	99.6 (98.8-100.4)	<0.001	61.3 (55.1-67.4)	<0.001	95.0 (92.2-97.8)	<0.001	68.8 (62.9-74.6)	<0.001	30.0 (24.2-35.8)	<0.001
50+	99.3 (98.2-100.3)	<0.001	53.8 (47.8-59.8)	<0.001	93.6 (90.7-96.6)	<0.001	45.1 (39.1-51.1)	<0.001	11.7 (7.8-15.5)	<0.001

Table S4c: Adjusted predicted probabilities of antigen positivity by age group and sex. Niue, 2025

		Tetanus max	
Sex	Age group (years)	Predicted probability (95% CI)	P-value
Male	<20	78.8 (64.8-92.7)	<0.001
	20-49	80.0 (71.7-88.3)	<0.001
	50+	84.2 (76.9-91.5)	<0.001
Female	<20	85.2 (71.8-98.6)	<0.001
	20-49	67.0 (58.4-75.6)	<0.001
	50+	52.1 (42.1-62.1)	<0.001




Figure S1: Seroprevalence of dengue serotypes by age group. Shading indicates 95% Confidence Intervals.




Figure S2: Seroprevalence of chikungunya and Zika by age group. Shading indicates 95% Confidence Intervals.




Figure S3: Seroprevalence of vaccine-preventable diseases by age group. Shading indicates 95% Confidence Intervals.